research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research 452 Braicitinib treatment reduced the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata
Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Blood donors on teratogenic drugs and donor deferral periods in a clinical situation
Some blood donors on teratogenic drugs may have unsafe drug levels, suggesting a need for better deferral policies.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Evaluation of Serum Ferritin, Creatinine and Liver Enzymes in Patients with ß- thalassemia After Administration of Deferasirox
Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS ) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research SnapshotDx Quiz: May 2020
BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Periocular Manifestations of Afatinib Therapy
Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
research Clinical Snippets
A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.
research Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.